The National Institute of Drug Abuse (NIDA) announced they are sponsoring a clinical trial testing whether Tirzepatide could effectively treat cannabis use disorder
Over half of corporate and multiemployer/public plans cover GLP-1s for diabetes only, while roughly one-third in each group extend coverage to both diabetes and weight loss
Preliminary experimental studies confirm that synthetically prepared SR18 maintains an ordered, -helical conformation under various solvent conditions and possesses the basic pharmaceutical properties desired of a potent lead peptide
b , Pharmacological characterization of 3 H-peptide 1 at the wild-type GLP-1R
Ozempic may not be appropriate for individuals with a history of eating disorders, significant gut motility issues, gallbladder disease, thyroid concerns, or those seeking sustainable, long-term metabolic health rather than medication-dependent weight loss
: L- 500